The selected epitopes were built with the N-terminal linked to a
galactose moiety, represented by Z (table 1), to form the glycoconjugate
structures. This strategy was adopted to improve the
immune response, as well as to the improve the side effects of
these molecules because they behave as adjuvants in the immune
response.